Description:
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor:
Clarity PharmaceuticalsContacts:
Clarity Pharmaceuticalsclinicaltrials@claritypharmaceuticals.com
+61 (0) 2 9209 4037
Government Study Link:
NCT06056830 - Click here to see study onClinicalTrials.gov
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
United States 🇺🇸
17607 Gold Plaza, Omaha, Nebraska 68130, United States
Myrtle Beach, South Carolina, United States
Stanford, California 94305, United States
Principal Investigator
Hong Song, MD, Ph.D.
Dallas, Texas, United States
Principal Investigator
Alexander Parker, MD
Phoenix, Arizona, United States
Principal Investigator
Jack Andrews, MD
Nashville, Tennessee, United States
Principal Investigator
David Morris, MD
Utah, United States
Principal Investigator
Dustin L. Boothe, MD
Los Angeles, California, United States
Principal Investigator
Gholam Berenji, MD
San Antonio, Texas, United States
Principal Investigator
Naveen Kella, MD
Michigan, United States
Principal Investigator
Brian R. Lane MD
Grand Rapids, Michigan 49503, United States
Principal Investigator
Harshad Kulkarni, M.D.
Tulsa, Oklahoma 74146, United States
Principal Investigator
Shaun GS Grewal, MD
Dallas, Texas 75390, United States
Principal Investigator
Orhan K. Oz, MD, PhD
Glenview, Illinois 60026, United States
Principal Investigator
Brian Helfand, MD
Madison, Wisconsin 53792, United States
Principal Investigator
Steve Y Cho, MD
Jacksonville, Florida, United States
Principal Investigator
Ephraim Parent, MD, PhD
Rochester, Minnesota, United States
Principal Investigator
Jeffrey Karnes, MD
Indianapolis, Indiana, United States
Australia 🇦🇺
Sydney, New South Wales, Australia
Woolloongabba, Queensland, Australia
Principal Investigator
Professor Ian Vela, MBBS, PhD